Ключевые слова
Как цитировать
Аннотация
В статье обсуждается возможность проведения неоадьювантной химиотерапии у больных раком ободочной кишки и у больных раком прямой кишки без дополнительного использования лучевой терапии. Анализируются возможные риски и преимущества такого подхода, приводятся данные доступных клинических исследований.Библиографические ссылки
Ando N., Kato H., Igaki H. et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907) // Ann Surg Oncol. - 2012. - Vol. 19. - P 68-74.
Andre T., Boni C., Navarro M. et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MosAIC trial // J Clin oncol. - 2009. - Vol. 27. - P. 3109-3116.
Belt E.J., van Stijn M.F., Bril H. et al. Lymph node negative colorectal cancers with isolated tumor deposits should be classified and treated as stage III // Ann Surg Oncol. - 2010. - Vol. 17. - P. 3203-3211.
Bertagnolli M.M., Niedzwiecki D., Compton C.C. et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803 // J Clin Oncol. - 2009. - Vol. 27. - P. 1814-1821.
Betge J., Kornprat P, Pollheimer M.J. et al. Tumor Budding is an Independent Predictor of Outcome in AJCC/ UICC Stage II Colorectal Cancer // Ann Surg Oncol. - 2012. - Vol. 19. - P. 3706-3712.
Betge J., Pollheimer M.J., Lindtner R.A. et al. Intramural and extramural vascular invasion in colorectal cancer: prognostic significance and quality of pathology reporting // Cancer. - 2012. - Vol. 118. - P. 628-368.
Birgisson H., Pahlman L., Gunnarsson U., Glimelius B. Occurrence of second cancers in patients treated with radiotherapy for rectal cancer // J Clin Oncol. - 2005. - Vol. 23. - P. 6126-6131.
Bokemeyer C., Bondarenko I., Makhson A. et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer // J Clin Oncol. - 2009. - Vol. 27. - P. 663-671.
Boras Z., Kondza G., Sisljagic V. et al. Prognostic factors of local recurrence and survival after curative rectal cancer surgery: a single institution experience // Coll Antropol. - 2012. - Vol. 36. - P 1355-1361.
Bosset J.F., Collette L., Calais G. et al. Chemotherapy with preoperative radiotherapy in rectal cancer // N Engl J Med. - 2006. - Vol. 355. - P 1114-1123.
Burton S., Norman A.R., Brown G. et al. Predictive poor prognostic factors in colonic carcinoma // Surg Oncol. - 2006. - Vol. 15. - P. 71-78.
Cercek A., Weiser M., Goodman K., Reidy D. Complete pathologic response in the primary of rectal or colon cancer treated with FOLFOX without radiation. // J Clin Oncol (Meeting Abstracts). - 2010. - Vol. 28 (15S Suppl, May 20 Supplement): 297s (Abstr 3649).
Ceyhan G.O., Liebl F., Maak M. et al. The severity of neural invasion is a crucial prognostic factor in rectal cancer independent of neoadjuvant radiochemotherapy // Ann Surg. - 2010. - Vol. 252. - P. 797-804.
Colorectal Cancer Chemotherapy Study Group of Japan. Results of a randomized trial with or without 5-FU-based preoperative chemotherapy followed by postoperative chemotherapy in resected colon and rectal carcinoma // Jpn J Clin Oncol. - 2003. - Vol. 33. - P. 288-296.
Compton C. Prognostic factors in cancer. // 3rd Edition. Hoboken (NJ) Wiley-Liss. -2006.
Cunningham D., Allum W.H., Stenning S.P et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer // N Engl J Med. - 2006. - Vol. 355. - P. 11-20.
Das P., Skibber J.M., Rodriguez-Bigas M.A. et al. Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer // Am J Clin Oncol. - 2006. - Vol. 29. - P. 219-224.
Dresen R.C., Peters E.E., Rutten H.J. et al. Local recurrence in rectal cancer can be predicted by histopathologi-cal factors // Eur J Surg Oncol. - 2009. - Vol. 35. - P. 1071-1077.
Fahmy R.G., Dass C.R., Sun L.Q. et al. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth // Nat Med. - 2003.- Vol. 9. - P. 1026-1032.
Finlay I.G., Meek D., Brunton F., McArdle C.S. Growth rate of hepatic metastases in colorectal carcinoma // Br J Surg. - 1988. - Vol. 75. - P. 641-644.
Foxtrot Collaborative Group Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial // Lancet Oncol. - 2012. - Vol. 13. - P. 1152-1160.
Frasson M., Garcia-Granero E., Roda D. et al. Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer // Cancer. - 2011. - Vol. 117. - P. 3118-3125.
Gerard J.P, Conroy T., Bonnetain F. et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203 // J Clin Oncol. - 2006. - Vol. 24. - P. 4620-4625.
Giacchetti S., Perpoint B., Zidani R. et al. Phase III multicenter randomized trial of oxaliplatin added to chrono-modulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer // J Clin Oncol. - 2000. - Vol. 18. - P. 136-147.
Glynne-Jones R., Anyamene N., Moran B., Harrison M. Neoadjuvant chemotherapy in MRI-staged high-risk rectal cancer in addition to or as an alternative to preoperative chemoradiation? // Ann Oncol. - 2012. - Vol. 23. -P 2517-2526.
Gryfe R., Kim H., Hsieh E.T. et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer // N Engl J Med. - 2000. - Vol. 342. - P. 69-77.
Horn A., Dahl O., Morild I. Venous and neural invasion as predictors of recurrence in rectal adenocarcinoma // Dis Colon Rectum. - 1991. - Vol. 34. - P. 798-804.
Hunter C.J., Garant A., Vuong T. et al. Adverse features on rectal MRI identify a high-risk group that may benefit from more intensive preoperative staging and treatment // Ann Surg Oncol. - 2012. - Vol. 19. - P. 1199-1205.
Ishii Y, Hasegawa H., Endo T. et al. Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer // Eur J Surg Oncol. - 2010. - Vol. 36. - P. 1061-1065.
Jass J.R., Do K.A., Simms L.A., Iino H. et al. Morphology of sporadic colorectal cancer with DNA replication errors // Gut. - 1998. - Vol. 42. - P. 673-679.
Kawai K., Kitayama J., Tsuno N.H., et al. Thrombocytosis before pre-operative chemoradiotherapy predicts poor response and shorter local recurrence-free survival in rectal cancer // Int J Colorectal Dis. - 2013. - Vol. 28. - P 527-535.
Kim S.H., Bae K.B., Kim J.M. et al. Oncologic Outcomes and Risk Factors for Recurrence after Tumor-specific Mesorectal Excision of Rectal Cancer: 782 Cases // J Korean Soc Coloproctol. - 2012. - Vol. 28. - P. 100-107.
Koca D., Binicier C., Oztop I. et al. Prognostic factors affecting recurrence and survival in patients with locally advanced rectal cancer // J BUON. 2012. - Vol. 17. - P. 291-298.
Koopman M., Kortman G.A., Mekenkamp L. et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer // Br J Cancer. - 2009. - Vol. 100. - P. 266-273.
Kuebler J.P, Wieand H.S., O’Connell M.J. et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07 // J Clin Oncol. - 2007. - Vol. 25. - P. 2198-2204.
Kusters M., Valentini V., Calvo F.A. et al. Results of European pooled analysis of IORT-containing multimodality treatment for locally advanced rectal cancer: adjuvant chemotherapy prevents local recurrence rather than distant metastases // Ann Oncol. - 2010. - Vol. 21. - P. 1279-1284.
Lee J.H., Jang H.S., Kim J.G. et al. Lymphovascular invasion is a significant prognosticator in rectal cancer patients who receive preoperative chemoradiotherapy followed by total mesorectal excision // Ann Surg Oncol. - 2012. -Vol. 19. - P. 1213-1221.
Li M., Li J.Y, Zhao A.L., Gu J. Colorectal cancer or colon and rectal cancer? Clinicopathological comparison between colonic and rectal carcinomas // Oncology. - 2007. - Vol. 73. - P. 52-57.
Lou Z., Meng R.G., Zhang W. et al. Preoperative carcino-embryonic antibody is predictive of distant metastasis in pathologically T1 colorectal cancer after radical surgery // World J Gastroenterol. - 2013. - Vol. 19. - P. 389393.
Mathis K.L., Larson D.W., Dozois E.J. et al. Outcomes following surgery without radiotherapy for rectal cancer // Br J Surg. - 2012. - Vol. 99. - P 137-143.
Maughan T.S., Adams R.A., Smith C.G. et al. Addition of cetuximab to oxaliplatin-based first-line combination che motherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial // Lancet. - 2011. - Vol. 377. - P. 2103-2114.
Miki C., Tanaka K., Inoue Y et al. Perioperative host-tumor inflammatory interactions: a potential trigger for disease recurrence following a curative resection for colorectal cancer // Surg Today. - 2008. - Vol. 38. - P. 579-584.
Nakamura T., Mitomi H., Kikuchi S. et al. Evaluation of the usefulness of tumor budding on the prediction of metastasis to the lung and liver after curative excision of colorectal cancer // Hepatogastroenterology. - 2005. - Vol. 52. - P. 1432-1435.
National Cancer Comprehensive Network. Clinical practice guidelines in oncology: rectal cancer.v 1.2014.URL: http://www.nccn.org (дата обращения 01.10.2013).
Ngan S.Y., Burmeister B., Fisher R.J. et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with t3 rectal cancer: trans-tasman radiation oncology group trial 01.04 // J Clin Oncol. - 2012. - Vol. 30. - P. 3827-3833.
Okuyama T., Oya M., Ishikawa H. Budding as a useful prognostic marker in pT3 well- or moderately-differentiated rectal adenocarcinoma // J Surg Oncol. - 2003. - Vol. 83. - P. 42-47.
Pantel K., Cote R.J., Fodstad O. Detection and clinical importance of micrometastatic disease // J Natl Cancer Inst. - 1999. - Vol. 91. - P 1113-1124.
Quirke P., Steele R., Monson J., Grieve R., Khanna S., Couture J., O’Callaghan C., Myint A.S., Bessell E., Thompson L.C., Parmar M. et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial // Lancet. - 2009. - Vol. 373. - P. 821-828.
Ratto C., Ricci R., Rossi C., Morelli U. et al. Mesorectal microfoci adversely affect the prognosis of patients with rectal cancer // Dis Colon Rectum. - 2002. - Vol. 45. - P 733-742; discussion 742-743.
Roh M.S., Colangelo L.H., O’Connell M.J. et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03 // J Clin Oncol. - 2009. - Vol. 27. - P. 5124-5130.
Sargent D.J., Marsoni S., Monges G. et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer // J Clin Oncol. - 2010. - Vol. 28. - P. 3219-3226.
Sauer R., Liersch T, Merkel S. et al. Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow-Up of 11 Years // J Clin Oncol. - 2012. - Vol. 30. - P 19261933.
Schrag D., Weiser M., Goodman K., Reidy D. Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer // J Clin Oncol (Meeting Abstracts). - 2010. - Vol. 28 (15S Suppl, May 20 Supplement) - 263s (Abstr 3511).
Schuhmacher C., Gretschel S., Lordick F. et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954 // J Clin Oncol. - 2010. - Vol. 28. - P. 5210-5218.
Sebag-Montefiore D., Stephens R.J., Steele R. et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial // Lancet. - 2009. - Vol. 373. - P. 811-820.
Seymour M.T., Maughan T.S., Ledermann J.A. et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial // Lancet. - 2007. - Vol. 370. - P. 143-152.
Song S., Hong J.C., McDonnell S.E. et al. Combined Modality Therapy for Rectal Cancer: The Relative Value of Posttreatment Versus Pretreatment CEA as a Prognostic Marker for Disease Recurrence // Ann Surg Oncol. 2012. - Vol. 19. - P. 2471-2476.
Song Y.X., Gao P., Wang Z.N., Liang J.W. et al. Can the tumor deposits be counted as metastatic lymph nodes in the UICC TNM staging system for colorectal cancer? // PLoS One. - 2012. - Vol. 7. - P. e34087.
Sun L.C., Chu K.S., Cheng S.C. et al. Preoperative serum carcinoembryonic antigen, albumin and age are supplementary to UICC staging systems in predicting survival for colorectal cancer patients undergoing surgical treatment // BMC Cancer. - 2009. - Vol. 9. - P. 288.
Syk E., Lenander C., Nilsson P.J. et al. Tumour budding correlates with local recurrence of rectal cancer // Colorectal Dis. - 2011. - Vol. 13. - P. 255-262.
Tanaka K., Shimada H., Miura M. et al. Metastatic tumor doubling time: most important prehepatectomy predictor of survival and nonrecurrence of hepatic colorectal cancer metastasis // World J Surg. - 2004. - Vol. 28. - P. 263-270.
Tanaka M., Hashiguchi Y, Ueno H. et al. Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage II, T3 colon cancer // Dis Colon Rectum. - 2003. - Vol. 46. - P. 1054-1059.
Taylor F.G., Quirke P, Heald R.J. et al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study // Ann Surg. - 2011. - Vol. 253. - P. 711-719.
van Gijn W., Marijnen C.A., Nagtegaal I.D. et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial // Lancet Oncol. - 2011. - Vol. 12. - P. 575-582.
Weitz J., Koch M., Kienle P. et al. Detection of hematogenic tumor cell dissemination in patients undergoing resection of liver metastases of colorectal cancer // Ann Surg. - 2000. - Vol. 232. - P. 66-72.
Wu Z.Y, Wan J., Zhao G. et al. Risk factors for local recurrence of middle and lower rectal carcinoma after curative resection // World J Gastroenterol. - 2008. - Vol. 14. - P. 4805-4809.
Zeamari S., Roos E., Stewart F.A. Tumour seeding in peritoneal wound sites in relation to growth-factor expression in early granulation tissue // Eur J Cancer. - 2004. - Vol. 40. - P. 1431-1440.
Zlobec I., Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget // Oncotarget. - 2010. - Vol. 1. - P. 651-661.
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2014